Program
olipudase alfa
Also written as “rhASM”, “Olipudase alfa” and “GZ402665”.
Its studies are mostly in Niemann-Pick Diseases · Niemann-Pick Disease, Type A, led by Sanofi.
Furthest: phase 3, since Nov 26, 20136 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 60 open or running | phase 3since Nov 26, 2013 | Dec 11, 2006 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2006First study: phase 1 study in Niemann-Pick DiseasesFirst studyNCT00410566 · 11 enrolled · United States
- Nov 5, 2012Phase 1 study in Human Acid Sphingomyelinase DeficiencyNCT01722526 · 5 enrolled · United States, United Kingdom
- Nov 26, 2013Phase 2 study in Niemann-Pick Disease, Type ANCT02004704 · 25 enrolled · United States, Belgium, Brazil and more
- Nov 26, 2013Phase 3 study in Niemann-Pick Disease, Type ANCT02004691 · 36 enrolled · United States, Argentina, Australia and more
- Nov 7, 2014Phase 2 study in Niemann-Pick Disease, Type ANCT02292654 · 20 enrolled · United States, Brazil, France and more
- Apr 22, 2025Phase 2 study in Niemann-Pick DiseasesNCT06949358 · 3 enrolled · France
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06949358Niemann-Pick Diseases · France | 2 | Completed | Apr 8, 2025 | 3 |
| NCT02292654Niemann-Pick Disease, Type A · United States, Brazil, France and more | 2 | Completed | Dec 9, 2019 | 20 |
| NCT02004704Niemann-Pick Disease, Type A · United States, Belgium, Brazil and more | 2 | Completed | Sep 6, 2023 | 25 |
| NCT02004691Niemann-Pick Disease, Type A · United States, Argentina, Australia and more | 3 | Completed | Mar 15, 2021 | 36 |
| NCT01722526Human Acid Sphingomyelinase Deficiency · United States, United Kingdom | 1 | Completed | Jan 2014 | 5 |
| NCT00410566Niemann-Pick Diseases · United States | 1 | Terminated | Mar 2009 | 11 |
How it is read
Names in the registry
- “rhASM”, 5 entries
- “Olipudase alfa”, 3 entries
- “GZ402665”, 1 entry
- “Recombinant human acid sphingomyelinase”, 1 entry
Conditions, from the studies’ own filings
- Niemann-Pick Diseases, 3 studies
- Niemann-Pick Disease, Type A, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.